



## Lewis Group – 3Q trading update

Date: 27 January 2022

**Key message: Revenue growth in line with FY22E forecasts. Debtor costs improve considerably. No changes to HEPS outlook.**

- Lewis announced a strong trading update for the nine months to December 2021 – merchandise sales grew by 12.7% compared to the same period the prior year. Comparable stores sales grew by 10.3%. Black Friday sales remained robust, supporting 3Q sales growth of 3.6% on the comparative period. 3Q21 saw abnormally strong Black Friday sales following lockdown (+16.6%), therefore growth of 3.6% off this base is impressive. 3Q22 sales were up 20.7% on 3Q20. Sales growth is currently running ahead of our 10.3% forecast for FY22E.
- Credit sales are recovering strongly (+16%) as anticipated given the higher level of cash transacting during COVID-19 in the prior year when consumer liquidity was boosted. Growth is broadly in line with our 15% growth in FY22E.
- Other revenue (finance income, insurance income and ancillary services) achieved modest growth of 1.3% for the nine months. This is below our growth estimate of 4.6% for FY22E. We do, however, anticipate a growth recovery in 4Q following stronger credit sales and the repo rate hike in November 2021 (and potentially later today).
- Total revenue has grown 8% in the nine months which is in line with our FY22E forecast.
- The quality of the debtors book continues to improve, as envisaged. Debtor costs are down 20.5% for the nine-month period. We are forecasting an 18% decline for FY22E. Collection rates rose to 79.7% in 3Q22 (75.6% in 3Q21).
- With the trends broadly in line with our FY22E estimates, we see no reason to amend our earnings forecast for FY22E. A greater decline in debtors costs provides some comfort. 4Q is a slower revenue period for Lewis, certainly compared to 3Q.
- We anticipate modest headline earnings growth of 6% and 11% in FY22E and FY23E impacted by a low repo rate, a depressed cost base in FY21 and store interruptions due to COVID-19 and civil unrest (to date R68.6m of claims has been received from a total of R78.8m). Post the buyback it translates into HEPS growth of 24% and 23%. This puts the stock on an attractive 16-month forward PE of 5x. We value the stock on a DFCF basis, deriving a fair value range of R65.68 to R72.75.

**Sven Thordsen, CFA**  
+44 (0) 752 367 6780

[sven.thordsen@chronux.co.za](mailto:sven.thordsen@chronux.co.za)

Price (27/01/2022): R46.90  
Market cap R3095m  
Shares in issue 66mn

*Sponsored Research: Chronux Research is compensated by certain corporates to produce objective and impartial research. A Recommendation is not provided. Earnings forecasts and a valuation are the independent view of the analyst, based on their view of all factors that could influence earnings and peer comparisons.*

ZARmn (to March)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	4,280	4,437	4,670	5,089	5,658
EBITDA	629	1,039	1,155	1,288	1,428
Normalised earnings	205	463	493	547	610
Normalised HEPS (ZAc)	260	617	764	935	1,119
PE Ratio	6.8	7.5	6.1	5.0	4.2
Dividend (ZAc)	185	328	420	514	615
Dividend yield	10.4%	7.1%	9%	11.0%	13.1%

Source: Company data, Chronux Research estimates

**Disclaimer:**

Chronux Research (Pty) Ltd or its affiliates have been commissioned by the Company to produce this research for a fee. This report is not investment, financial, accounting or tax advice and is provided for information purposes only. In preparing this report we did not take your specific needs and investment objectives into account. Any prices or quotations provided are indicative only and may not be used or relied on for any purposes, including valuation purposes. Opinions expressed in this communication may change without any notice. This communication is not a solicitation to buy or sell any product. To the extent permitted by the law, Chronux Research Pty. Ltd. and/or the author(s) accept no responsibility or liability (in negligence or otherwise) for loss or damage resulting from the use of or relating to any error in the information provided. This information has been prepared in good faith and is based on information obtained from third party sources. Any modelling, scenario analysis past or simulated past performance (including back-testing) contained in this information is no indication of future performance. Analysts at Chronux Research might own direct exposure to companies they cover. This product may not be eligible for distribution in all jurisdictions and is directed at Institutional and Professional investors who have the experience as defined by the applicable law and/or regulation in the relevant jurisdiction. It is not deemed suitable for Retail or non-qualified investors and may not be distributed into any jurisdiction where the information is not permitted. This communication is for the intended recipient only and if you have received this communication in error or in an unlawful manner the report must be destroyed, and the author notified immediately. These disclaimers and exclusions shall be governed and construed in accordance with South African law. If any provisions of these disclaimers and exclusions shall be unlawful, void or for any reason unenforceable then that provision shall be deemed severable and shall not affect the validity and enforceability of the remaining provisions. © Chronux Research Pty. Ltd. All rights of Chronux Research Pty. Ltd are reserved.